CompletedPhase 3NCT04311671
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Studying Filariasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medicines Development for Global Health
- Principal Investigator
- Tony Ukety, MD, DO, MPHCentre de Recherche en Maladies Tropicales de l'Ituri
- Intervention
- Moxidectin(drug)
- Enrollment
- 12979 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2021 – 2024
Study locations (2)
- Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire, Abidjan, Côte d’Ivoire
- Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Democratic Republic of the Congo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04311671 on ClinicalTrials.govOther trials for Filariasis
Additional recruiting or active studies for the same condition.